melphalan and olaparib

melphalan has been researched along with olaparib* in 3 studies

Other Studies

3 other study(ies) available for melphalan and olaparib

ArticleYear
The PARP inhibitor olaparib enhances the cytotoxicity of combined gemcitabine, busulfan and melphalan in lymphoma cells.
    Leukemia & lymphoma, 2017, Volume: 58, Issue:11

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; DNA Damage; DNA Repair; Drug Synergism; Gemcitabine; Humans; Lymphoma; Male; Melphalan; Middle Aged; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Reactive Oxygen Species; Tumor Cells, Cultured

2017
Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer.
    Journal of the National Cancer Institute, 2016, Volume: 108, Issue:11

    Although BRCA1-deficient tumors are extremely sensitive to DNA-damaging drugs and poly(ADP-ribose) polymerase (PARP) inhibitors, recurrences do occur and, consequently, resistance to therapy remains a serious clinical problem. To study the underlying mechanisms, we induced therapy resistance in patient-derived xenograft (PDX) models of BRCA1-mutated and BRCA1-methylated triple-negative breast cancer.. A cohort of 75 mice carrying BRCA1-deficient breast PDX tumors was treated with cisplatin, melphalan, nimustine, or olaparib, and treatment sensitivity was determined. In tumors that acquired therapy resistance, BRCA1 expression was investigated using quantitative real-time polymerase chain reaction and immunoblotting. Next-generation sequencing, methylation-specific multiplex ligation-dependent probe amplification (MLPA) and Target Locus Amplification (TLA)-based sequencing were used to determine mechanisms of BRCA1 re-expression in therapy-resistant tumors.. BRCA1 protein was not detected in therapy-sensitive tumors but was found in 31 out of 42 resistant cases. Apart from previously described mechanisms involving BRCA1-intragenic deletions and loss of BRCA1 promoter hypermethylation, a novel resistance mechanism was identified in four out of seven BRCA1-methylated PDX tumors that re-expressed BRCA1 but retained BRCA1 promoter hypermethylation. In these tumors, we found de novo gene fusions that placed BRCA1 under the transcriptional control of a heterologous promoter, resulting in re-expression of BRCA1 and acquisition of therapy resistance.. In addition to previously described clinically relevant resistance mechanisms in BRCA1-deficient tumors, we describe a novel resistance mechanism in BRCA1-methylated PDX tumors involving de novo rearrangements at the BRCA1 locus, demonstrating that BRCA1-methylated breast cancers may acquire therapy resistance via both epigenetic and genetic mechanisms.

    Topics: Animals; Antineoplastic Agents; BRCA1 Protein; Cisplatin; DNA Methylation; Drug Resistance, Neoplasm; Female; Gene Expression; Gene Fusion; Genes, BRCA1; Humans; Melphalan; Mice; Mutation; Neoplasm Transplantation; Nimustine; Phthalazines; Piperazines; Promoter Regions, Genetic; Triple Negative Breast Neoplasms

2016
Liquid chromatography-tandem mass spectrometric assay for the PARP-1 inhibitor olaparib in combination with the nitrogen mustard melphalan in human plasma.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2011, Jul-01, Volume: 879, Issue:21

    A bioanalytical assay for the new poly(ADP-ribose) polymerase-1 inhibitor olaparib in combination with melphalan was developed and validated. For the quantitative assay, human plasma samples were pre-treated on ice using protein precipitation with 2% (v/v) acetic acid in acetonitrile containing erlotinib and melphalan-d₈ as internal standards. The extract was diluted with water and injected into the chromatographic system. This system consisted of a sub-2 μm particle, trifunctional bonded octadecyl silica column with an isocratic elution using 0.01% (v/v) of formic acid in a mixture of water and methanol. The eluate was transferred into the electrospray interface with positive ionization and the analyte was detected in the selected reaction monitoring mode of a triple quadrupole mass spectrometer. The assay was validated in a 10-5000 ng/ml calibration range for both drugs. The lowest level of this range corresponded to the lower limit of quantification. Within day precisions were 3.0-9.3%, between day precisions 6.0-9.8% and accuracies were between 101 and 110% for the whole calibration range. After validation the assay was used to assess the pharmacokinetics of olaparib in a patient with metastatic breast carcinoma. In addition, systemic exposure of melphalan was monitored in patients subjected to isolated hepatic perfusion with this drug. Both applications show that the new assay can be applied for human pharmacokinetic studies for both drugs.

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chromatography, Liquid; Drug Stability; Female; Humans; Least-Squares Analysis; Melphalan; Middle Aged; Neoplasms; Phthalazines; Piperazines; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry

2011